|
Alaska Angel
I think MD Anderson looks at EGFR in its BRCA+ patients as they seem to often be triple negative and have an increased incidence of EGFR positivity...Also it gives them a possible targetted drug to treat with.
As neither Iressa, Tarceva and Erbitux is officially approved for breast cancer I think they feel testing would not be "clinically relevant" But if you don't test, you don't find out and you don't make progress against the disease.
My two cents.
|
Threaded Mode